Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Life expectancy \>/= 12 weeks
ECOG performance status of 0 or 1
Histologic or cytologic documentation of locally advanced, or metastatic solid malignancy that has relapsed after or failed to respond to at least one prior regimen or for which there is no standard therapy
Adequate hematologic and end organ function
For female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use an effective form of contraception and to continue its use until 90 days after the last dose of study treatment
Consent to provide archival tissue
You may not be if
Prior use of any monoclonal antibody within 4 weeks before Cycle 1, Day 1
Experimental therapy within 4 weeks prior to Cycle 1, Day 1
Palliative radiotherapy within 2 weeks prior to Cycle 1, Day 1
Prior anti-cancer therapy within 4 weeks prior to Cycle 1, Day 1
Major surgical procedure or trauma within 4 weeks prior to Cycle 1, Day 1. All wounds must be fully healed on Cycle 1, Day 1.
Evidence of significant, uncontrolled concomitant diseases which could affect compliance with the protocol or interpretation of results, including significant cardiovascular disease or pulmonary disease
Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at screening or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior to Cycle 1, Day 1
History of other malignancy which could affect compliance with the protocol or interpretation of results. Patients with a history of curatively treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix are allowed. Patients with a malignancy that has been treated with curative intent will also be allowed if the malignancy has been in remission without treatment for \>/= years prior to Cycle 1, Day 1.
Presence of positive test results for Hepatitis B (Hepatitis B surface antigen \[HBsAg\] and/or total HB core antibody \[anti-HB-c\]) or Hepatitis C (Hepatitis C virus \[HCV\] antibody serology testing). Patients positive for anti-HB-c are eligible only if PCR is negative for HBV DNA.
Known history of HIV seropositive status
Primary CNS malignancy, or untreated/active CNS metastases
Pregnancy, lactation or breastfeeding
Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications
